Utilização de terapêuticas comprovadamente úteis no tratamento da coronariopatia aguda: comparação entre diferentes regiões brasileiras. Análise do Registro Brasileiro de Síndromes Coronarianas Agudas (BRACE - Brazilian Registry on Acute Coronary Syndromes)

Nicolau, José Carlos; Franken, Marcelo; Lotufo, Paulo A.; Carvalho, Antônio Carlos; Neto, J A Marin; Lima, Felipe Gallego; Dutra, Óscar Pereira; Knobel, E; Oliveira, César Cardoso de; Timerman, Sérgio; Stefanini, Edson

doi:10.1590/s0066-782x2012000400001

Cited by 37 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They have also reported lower prescription rates of beta-blockers and thienopyridines. When compared to two other Brazilian registries 2,3 recently published, the drug prescription rates were higher in this registry, which can be explained by the method of selecting the centers and the profile of patients 3 .…”

Section: Discussionmentioning

confidence: 63%

“…Usually, ASA is highly used in all Brazilian 2,3 and international 14,16 registries. In this study sample, a high initial prescription rate of p2y12 inhibitors was observed, and, as compared to those registries previously published, that occurred to the detriment of the use of glycoprotein (GP) IIb/IIIa inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…In 2009, acute myocardial infarction (AMI) was the second major cause of death (96,386 individuals) 2 , representing an incidence of 48 deaths per 100,000 inhabitants 1 . In addition to the loss of lives, the social costs are worthy of note; for example, chest pain was the cause of approximately 100,000 visits to basic health care units 1 and more than 200,000 hospitalizations in 2010 3 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry

Wang¹,

Neuenschwander²,

Filho³

et al. 2014

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

BackgroundThe recommendations in guidelines are based on evidence; however, there is a gap between recommendations and clinical practice.ObjectiveTo describe the practice of prescribing evidence-based treatments for patients with acute coronary syndrome in Brazil.MethodsThis study carried out a subanalysis of the ACCEPT registry, assessing epidemiological data and the prescription rate of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (IAT1RB), and statins. In addition, the quality of myocardial reperfusion in ST-segment elevation myocardial infarction was evaluated.ResultsThis study assessed 2,453 patients. The prescription rates of acetylsalicylic acid, p2y12 inhibitors, antithrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors/IAT1RB, and statins were as follows: in 24 hours - 97.6%, 89.5%, 89.1%, 80.2%, 67.9% and 90.6%; and at six months - 89.3%, 53.6%, 0%, 74.4%, 57.6% and 85.4%, respectively. Regarding ST-segment elevation myocardial infarction, only 35.9% and 25.3% of the patients underwent primary angioplasty and thrombolysis, respectively, within the recommended times.ConclusionThis registry showed high initial prescription rates of antiplatelet drugs, antithrombotic drugs, and statins, and lower prescription rates of beta-blockers and angiotensin-converting enzyme inhibitors/IAT1RB. Independently of the class, the use of all drugs decreased by six months. Most patients with ST-segment elevation myocardial infarction did not undergo myocardial reperfusion within the time recommended.

show abstract

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry

Wang¹,

Neuenschwander²,

Filho³

et al. 2014

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…These records have become major documents that show the demography of the disorders involved 2, 3, 8 . The initial results of these records demonstrate the diversity of treatments conducted at a national level, including the regional inequality in the employment of reperfusion therapies 2 . The use of these therapies relates, on the other hand, to lower mortality and lower rates of complications in the immediate follow-up of patients 3,8 .…”

mentioning

confidence: 99%

Implementation of Multicenter Records in the Therapeutic Cardiovascular Assessment in Brazil

Moreira¹

2013

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial

Nicolau

Furtado

Silva

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundLeft ventricular ejection fraction (LVEF) is a major determinant of long‐term prognosis after ST‐segment elevation myocardial infarction (STEMI). STEMI patients with reduced LVEF have a poor prognosis, despite successful reperfusion and the use of renin‐angiotensin‐aldosterone inhibitors.HypothesisIntracoronary infusion of bone marrow–derived mononuclear cells (BMMC) may improve LVEF in STEMI patients successfully reperfused.MethodsThe main inclusion criteria for this double‐blind, randomized, multicenter study were patient age 30 to 80 years, LVEF ≤50%, successful angioplasty of infarct‐related artery, and regional dysfunction in the infarct‐related area analyzed before cell injection. Cardiac magnetic resonance imaging was used to assess LVEF, left ventricular volumes, and infarct size at 7 to 9 days and 6 months post–myocardial infarction.ResultsOne hundred and twenty‐one patients were included (66 patients in the BMMC group and 55 patients in the placebo group). The primary endpoint, mean LVEF, was similar between both groups at baseline (44.63% ± 10.74% vs 42.23% ± 10.33%; P = 0.21) and at 6 months (44.74% ± 12.95 % vs 43.50 ± 12.43%; P = 0.59). The groups were also similar regarding the difference between baseline and 6 months (0.11% ± 8.5% vs 1.27% ± 8.93%; P = 0.46). Other parameters of left ventricular remodeling, such as systolic and diastolic volumes, as well as infarct size, were also similar between groups.ConclusionsIn this randomized, multicenter, double‐blind trial, BMMC intracoronary infusion did not improve left ventricular remodeling or decrease infarct size.

show abstract

Utilização de terapêuticas comprovadamente úteis no tratamento da coronariopatia aguda: comparação entre diferentes regiões brasileiras. Análise do Registro Brasileiro de Síndromes Coronarianas Agudas (BRACE - Brazilian Registry on Acute Coronary Syndromes)

Abstract: Background: Little is known in our country about regional differences in the treatment of acute coronary disease.

Cited by 37 publications

References 5 publications

Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry

Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry

Implementation of Multicenter Records in the Therapeutic Cardiovascular Assessment in Brazil

Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial

Contact Info

Product

Resources

About